Iberdomide, Daratumumab, Dexamethasone vs Daratumumab, Bortezomib, Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Results From EXCALIBER-RRMM Phase 3 Study

The EXCALIBER-RRMM clinical trial evaluated a combination therapy of iberdomide, daratumumab, and dexamethasone against daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. The trial demonstrated that adding the cereblon E3 ligase modulator iberdomide significantly improved minimal residual disease-negative complete response rates across diverse patient subgroups while maintaining a predictable and manageable safety profile. Based on these outcomes, the regulatory authority granted accelerated approval for this treatment combination as a new standard of care for patients experiencing early relapse.